Continuous Glucose Monitoring Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034
Description
The Global Continuous Glucose Monitoring Market was valued at USD 10.9 billion in 2024 and is estimated to grow at a CAGR of 15.9% to reach USD 47.1 billion by 2034.
Market growth is driven by the rising global diabetes burden, technological advancements in wearable monitoring systems, and increasing adoption of remote patient management solutions. Continuous glucose monitoring (CGM) systems provide real-time insights into glucose fluctuations, helping reduce the risk of hypoglycemia and enabling personalized diabetes care. Growing preference for minimally invasive monitoring and integration with mobile and digital health platforms is further accelerating market adoption. Supportive government initiatives promoting diabetes awareness, coupled with the aging population and rising prevalence of lifestyle disorders, are creating sustained demand for CGM devices across developed and emerging economies.
The market is primarily segmented by component, with sensors generating USD 5.52 billion in 2024. Sensors dominate due to their recurring use, improved accuracy, and increasing integration with mobile health apps and insulin delivery systems. Advancements such as extended sensor lifespan and better data analytics capabilities make them the most commercially significant component in CGM systems.
In terms of end use, home care settings accounted for the largest share in 2024, reaching USD 8.81 billion. The shift toward self-monitoring and the rise in telehealth adoption have significantly influenced demand from patients managing diabetes outside clinical environments, further boosting revenue in this segment.
North America Continuous Glucose Monitoring Market generated USD 5.13 billion in 2024, driven by high diabetes prevalence, robust healthcare spending, and faster adoption of advanced disease management technologies. The region benefits from favorable reimbursement frameworks, strong distribution networks, and rapid uptake of connected monitoring devices among both type 1 and type 2 diabetic patients. Increasing awareness of preventive health management and higher disposable income continue to support the region’s market leadership.
Key players in the Continuous Glucose Monitoring Market are Abbott Laboratories, Dexcom Inc., Medtronic plc, F. Hoffmann-La Roche Ltd., Senseonics Holdings Inc., A. Menarini Diagnostics, i-SENS Inc., Medtrum Technologies Inc., Shenzhen Sibionics Technology Co. Ltd., Sinocare, Zhejiang POCTech Co. Ltd., and MED TRUST. Leading companies in the Continuous Glucose Monitoring Market are heavily investing in research and development to enhance sensor accuracy, extend device lifespan, and improve user comfort. Many firms focus on developing compact, minimally invasive systems with seamless integration into smartphones and insulin delivery technologies to improve long-term adherence. Strategic collaborations and partnerships are also widely adopted to expand product capabilities and leverage complementary technologies across ecosystems.
Market growth is driven by the rising global diabetes burden, technological advancements in wearable monitoring systems, and increasing adoption of remote patient management solutions. Continuous glucose monitoring (CGM) systems provide real-time insights into glucose fluctuations, helping reduce the risk of hypoglycemia and enabling personalized diabetes care. Growing preference for minimally invasive monitoring and integration with mobile and digital health platforms is further accelerating market adoption. Supportive government initiatives promoting diabetes awareness, coupled with the aging population and rising prevalence of lifestyle disorders, are creating sustained demand for CGM devices across developed and emerging economies.
The market is primarily segmented by component, with sensors generating USD 5.52 billion in 2024. Sensors dominate due to their recurring use, improved accuracy, and increasing integration with mobile health apps and insulin delivery systems. Advancements such as extended sensor lifespan and better data analytics capabilities make them the most commercially significant component in CGM systems.
In terms of end use, home care settings accounted for the largest share in 2024, reaching USD 8.81 billion. The shift toward self-monitoring and the rise in telehealth adoption have significantly influenced demand from patients managing diabetes outside clinical environments, further boosting revenue in this segment.
North America Continuous Glucose Monitoring Market generated USD 5.13 billion in 2024, driven by high diabetes prevalence, robust healthcare spending, and faster adoption of advanced disease management technologies. The region benefits from favorable reimbursement frameworks, strong distribution networks, and rapid uptake of connected monitoring devices among both type 1 and type 2 diabetic patients. Increasing awareness of preventive health management and higher disposable income continue to support the region’s market leadership.
Key players in the Continuous Glucose Monitoring Market are Abbott Laboratories, Dexcom Inc., Medtronic plc, F. Hoffmann-La Roche Ltd., Senseonics Holdings Inc., A. Menarini Diagnostics, i-SENS Inc., Medtrum Technologies Inc., Shenzhen Sibionics Technology Co. Ltd., Sinocare, Zhejiang POCTech Co. Ltd., and MED TRUST. Leading companies in the Continuous Glucose Monitoring Market are heavily investing in research and development to enhance sensor accuracy, extend device lifespan, and improve user comfort. Many firms focus on developing compact, minimally invasive systems with seamless integration into smartphones and insulin delivery technologies to improve long-term adherence. Strategic collaborations and partnerships are also widely adopted to expand product capabilities and leverage complementary technologies across ecosystems.
Table of Contents
139 Pages
- Chapter 1 Methodology
- 1.1 Industry coverage
- 1.2 Market scope and definitions
- 1.3 Research design
- 1.4 Market size estimates and calculations
- 1.4.1 Approach 1: Company revenue share analysis
- 1.4.2 Approach 2: Demand-side modelling approach
- 1.4.3 Approach 2: Prevalence based approach
- 1.5 Key trends for market estimates
- 1.6 Forecast model
- 1.7 Primary research & validation
- 1.7.1 Primary sources
- 1.7.2 Data mining sources
- 1.7.2.1 Paid sources
- 1.7.2.2 Public sources
- Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Component trends
- 2.3 Type trends
- 2.4 End use trends
- 2.5 Regional trends
- Chapter 3 Industry Insights
- 3.1 Industry ecosystem
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing number of people suffering from diabetes globally
- 3.2.1.2 Rising demand for continuous monitoring devices
- 3.2.1.3 Technological advancements in devices
- 3.2.1.4 Increasing government initiatives to generate awareness regarding diabetes
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost related to devices
- 3.2.2.2 Stringent regulatory scenario
- 3.3 Growth potential analysis
- 3.3.1 By component
- 3.3.2 By type
- 3.3.3 By end use
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Technology landscape
- 3.5.1 Current technologies
- 3.5.2 Emerging technologies
- 3.5.2.1 Non-invasive continuous glucose monitoring
- 3.5.2.2 AI-Integrated smart systems for the management of prediabetes
- 3.6 Pricing analysis, 2024
- 3.7 Future market trends
- 3.7.1 Expansion beyond diabetes
- 3.7.1.1 Non-diabetic health enthusiasts
- 3.7.1.2 Pre-diabetic and at-risk individuals
- 3.7.2 Improved reimbursement and accessibility in emerging markets
- 3.7.3 AI and predictive analytics integration
- 3.8 Patent analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
- Chapter 4 Competitive Landscape
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.2.4 China
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
- Chapter 5 Continuous Glucose Monitoring Market, By Component
- 5.1 Transmitter
- 5.2 Sensors
- 5.3 Receiver
- Chapter 6 Continuous Glucose Monitoring Market, By Type
- 6.1 Prescription
- 6.2 Over the counter
- Chapter 7 Continuous Glucose Monitoring Market, By End Use
- 7.1 Hospitals
- 7.2 Home care settings
- 7.3 Diagnostic centers and clinics
- 7.4 Other end users
- Chapter 8 Continuous Glucose Monitoring Market, By Region
- 8.1 North America
- 8.2 Europe
- 8.3 Asia Pacific
- 8.4 Latin America
- 8.5 Middle East and Africa
- Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.1.1 Financial data
- 9.1.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.1.2 Product landscape
- 9.1.3 Strategic outlook
- 9.1.4 SWOT analysis
- 9.2 A. Menarini Diagnostics s.r.l
- 9.2.1 Financial data
- 9.2.2 Product landscape
- 9.2.3 Strategic outlook
- 9.2.4 SWOT analysis
- 9.3 Dexcom, Inc.
- 9.3.1 Financial data
- 9.3.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.3.2 Product landscape
- 9.3.3 Strategic outlook
- 9.3.4 SWOT analysis
- 9.4 F. Hoffmann-La Roche Ltd.
- 9.4.1 Financial data
- 9.4.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.4.2 Product landscape
- 9.4.3 Strategic outlook
- 9.4.4 SWOT analysis
- 9.5 i-SENS, Inc.
- 9.5.1 Financial data
- 9.5.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.5.2 Product landscape
- 9.5.3 Strategic outlook
- 9.5.4 SWOT analysis
- 9.6 MED TRUST
- 9.6.1 Financial data
- 9.6.2 Product landscape
- 9.6.3 SWOT analysis
- 9.7 Medtronic plc
- 9.7.1 Financial data
- 9.7.1.1 Sales revenue, 2022-2025 (USD Million)
- 9.7.2 Product landscape
- 9.7.3 Strategic outlook
- 9.7.4 SWOT analysis
- 9.8 Medtrum Technologies Inc.
- 9.8.1 Financial data
- 9.8.2 Product landscape
- 9.8.3 SWOT analysis
- 9.9 Senseonics Holdings, Inc.
- 9.9.1 Financial data
- 9.9.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.9.2 Product landscape
- 9.9.3 Strategic outlook
- 9.9.4 SWOT analysis
- 9.10 Shenzhen Sibionics Technology Co., Ltd
- 9.10.1 Financial data
- 9.10.2 Product landscape
- 9.10.3 Strategic outlook
- 9.10.4 SWOT analysis
- 9.11 Sinocare
- 9.11.1 Financial data
- 9.11.1.1 Sales revenue, 2021-2024 (USD Million)
- 9.11.2 Product landscape
- 9.11.3 Strategic outlook
- 9.11.4 SWOT analysis
- 9.12 Zhejiang POCTech Co., Ltd.
- 9.12.1 Financial data
- 9.12.2 Product landscape
- 9.12.3 SWOT analysis
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
